Clinic Roundup

Vertex Pharmaceuticals Inc., of Cambridge, Mass., said that its JAK3 inhibitor, VX-509, showed positive results in a Phase IIa trial in rheumatoid arthritis. The 12-week study met both of its primary endpoints: improvement in symptoms, and improvement from baseline disease activity score.